AU2001295310A1 - Aromatic derivatives with hiv integrase inhibitory properties - Google Patents

Aromatic derivatives with hiv integrase inhibitory properties

Info

Publication number
AU2001295310A1
AU2001295310A1 AU2001295310A AU9531001A AU2001295310A1 AU 2001295310 A1 AU2001295310 A1 AU 2001295310A1 AU 2001295310 A AU2001295310 A AU 2001295310A AU 9531001 A AU9531001 A AU 9531001A AU 2001295310 A1 AU2001295310 A1 AU 2001295310A1
Authority
AU
Australia
Prior art keywords
hiv integrase
inhibitory properties
aromatic derivatives
integrase inhibitory
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001295310A
Inventor
Blaise Magloire N'zemba
Gilles Sauve
Guy Sevigny
Jocelyn Yelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacor Inc
Original Assignee
Pharmacor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacor Inc filed Critical Pharmacor Inc
Publication of AU2001295310A1 publication Critical patent/AU2001295310A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4162,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52Two oxygen atoms
    • C07D239/54Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001295310A 2000-09-27 2001-09-25 Aromatic derivatives with hiv integrase inhibitory properties Abandoned AU2001295310A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA002321348A CA2321348A1 (en) 2000-09-27 2000-09-27 Aromatic derivatives with hiv integrase inhibitory properties
CA2321348 2000-09-27
PCT/CA2001/001367 WO2002026697A2 (en) 2000-09-27 2001-09-25 Aromatic derivatives with hiv integrase inhibitory properties

Publications (1)

Publication Number Publication Date
AU2001295310A1 true AU2001295310A1 (en) 2002-04-08

Family

ID=4167266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001295310A Abandoned AU2001295310A1 (en) 2000-09-27 2001-09-25 Aromatic derivatives with hiv integrase inhibitory properties

Country Status (4)

Country Link
US (1) US6528655B1 (en)
AU (1) AU2001295310A1 (en)
CA (1) CA2321348A1 (en)
WO (1) WO2002026697A2 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090124690A1 (en) * 2000-04-03 2009-05-14 Alberte Randall S Generation of Combinatorial Synthetic Libraries and Screening for Novel Proadhesins and Nonadhesins
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
CN1703395A (en) * 2002-08-09 2005-11-30 特兰斯泰克制药公司 Aryl and heteroaryl compounds and methods to modulate coagulation
US7414045B2 (en) * 2002-12-27 2008-08-19 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Substituted pyrimido[1,2-a]azepines useful as HIV integrase inhibitors
US7230133B2 (en) 2003-05-01 2007-06-12 Bristol-Myers Squibb Company Malonamides and malonamide derivatives as modulators of chemokine receptor activity
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
JP2007501844A (en) 2003-08-08 2007-02-01 トランス テック ファーマ,インコーポレイテッド Aryl and heteroaryl compounds, compositions and methods of use
WO2005014534A1 (en) * 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7208601B2 (en) * 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
EP1664154B1 (en) 2003-09-12 2009-05-27 Basf Se Highly functional, highly branched or hyperbranched polycarbonates and the production and use hereof
EP1725555B1 (en) 2004-03-08 2010-10-06 Prosidion Ltd. Pyrrolopyridine-2-carboxylic acid hydrazides as inhibitors of glycogen phosphorylase
DE602005013275D1 (en) 2004-12-02 2009-04-23 Prosidion Ltd Pyrrolopyridine-2-KARBONSÄUREAMIDE
EP1843734A4 (en) * 2005-02-03 2008-09-10 Signum Biosciences Inc Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
AU2006299918A1 (en) * 2005-10-13 2007-04-19 Wyeth Methods for preparing glutamic acid derivatives
JP5401652B2 (en) 2006-09-21 2014-01-29 タイメッド バイオロジクス インコーポレイテッド Protease inhibitor
US8759327B2 (en) 2007-04-16 2014-06-24 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
US9120744B2 (en) * 2007-04-16 2015-09-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism
AU2008266228A1 (en) * 2007-06-13 2008-12-24 Bristol-Myers Squibb Company Dipeptide analogs as coagulation factor inhibitors
CA2696321A1 (en) 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
EP2090606A1 (en) 2008-02-15 2009-08-19 Basf Se Highly functional polyetherols, method for their manufacture and application thereof
EP2161295A1 (en) 2008-09-05 2010-03-10 Basf Se Highly functional polyetherols, method for their manufacture and application thereof
CN101952347B (en) 2008-02-15 2015-02-18 巴斯夫欧洲公司 Highly functional polyetherols and the production and use thereof
CN102014897B (en) 2008-04-21 2015-08-05 西格纳姆生物科学公司 Compound, compositions and its preparation method
WO2011028740A1 (en) * 2009-09-03 2011-03-10 Glaxo Group Limited ENaC BLOCKERS
EP2444443A1 (en) 2010-10-18 2012-04-25 Basf Se Highly functional polyetherols, method for their manufacture and application thereof
US9085555B2 (en) 2011-01-04 2015-07-21 Novartis Ag Complement pathway modulators and uses thereof
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
CN104619698B (en) 2012-06-28 2016-08-31 诺华股份有限公司 Pyrrolidin derivatives and the purposes as complement pathway regulator thereof
CN105121429B (en) 2012-06-28 2017-12-12 诺华股份有限公司 Complement pathway conditioning agent and its purposes
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
EP2867229B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
EP2872503B1 (en) 2012-07-12 2018-06-20 Novartis AG Complement pathway modulators and uses thereof
US9718760B2 (en) 2012-10-31 2017-08-01 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 inhibitors and methods of use thereof
AU2018307807B2 (en) 2017-07-27 2024-05-02 Eastern Michigan University Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
WO2023028286A1 (en) * 2021-08-27 2023-03-02 Ut-Battelle, Llc Covalent inhibitors of coronavirus papain-like protease
CN114907344B (en) * 2022-05-09 2023-06-30 山东大学 Beta-carboline-1-propionic acid and indole derivatives, and preparation method and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2761687B1 (en) * 1997-04-08 2000-09-15 Centre Nat Rech Scient QUINOLEIN DERIVATIVES, ESPECIALLY HAVING ANTIVIRAL PROPERTIES, THEIR PREPARATIONS AND THEIR BIOLOGICAL APPLICATIONS
AU3366899A (en) * 1998-03-27 1999-10-18 Regents Of The University Of California, The Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
AU3546100A (en) * 1999-03-30 2000-10-23 Pharmacor Inc. Hydroxyphenyl derivatives with hiv integrase inhibitory properties
US6362165B1 (en) * 1999-03-30 2002-03-26 Pharmacor Inc. Hydroxyphenyl derivatives with HIV integrase inhibitory properties

Also Published As

Publication number Publication date
CA2321348A1 (en) 2002-03-27
US6528655B1 (en) 2003-03-04
WO2002026697A3 (en) 2002-05-16
WO2002026697A2 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU2001295310A1 (en) Aromatic derivatives with hiv integrase inhibitory properties
AU2001238595A1 (en) N-maleimidyl polymer derivatives
AU2002361992A1 (en) 1,4-dihydro-1,4-diphenylpyridine derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001280796A1 (en) Electrowetting-driven micropumping
AU2002221047A1 (en) Quinazolinone derivatives
AU2002221827A1 (en) Novel lactame-substituted pyrazolopyridine derivatives
AU2002216028A1 (en) Novel carbamate-substituted pyrazolopyridine derivatives
AU2002215218A1 (en) Isoxazole derivatives
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU6616400A (en) Hiv integrase inhibitors
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU3546100A (en) Hydroxyphenyl derivatives with hiv integrase inhibitory properties
AU2002213978A1 (en) Substituted C-cyclohexylmethylamine derivatives
AU2002212301A1 (en) Diazacycloalkanedione derivatives
AU2002349675A1 (en) Derivative having hiv integrase inhibitory activity
AU8009900A (en) Hiv integrase inhibitors
AU2001258563A1 (en) Chromatic-dispersion compensator
AU2002212959A1 (en) Cycloalkylfluorosulfonamide derivatives
AU2002221099A1 (en) Combination drugs
AU2002215212A1 (en) 1-methylcarbapenem derivatives
AU2001289937A1 (en) Substituted 1-aminobutan-3-ol derivatives